Annual report pursuant to Section 13 and 15(d)

8. STOCKHOLDERS' EQUITY (Details 3)

v3.19.1
8. STOCKHOLDERS' EQUITY (Details 3) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Total stock-based compensation expense $ 2,223,288 $ 1,561,659
Research and Development Expense    
Total stock-based compensation expense 292,739 380,925
Plasma centers [Member]    
Total stock-based compensation expense 34,797 47,330
Selling, General and Administrative Expense    
Total stock-based compensation expense 1,739,037 1,081,236
Cost of goods sold    
Total stock-based compensation expense $ 156,718 $ 52,168